Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 3Genitourinary 2Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1Lymphatic Metastasis 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
fluoroazomycin arabinoside × Genitourinary × Clear all
NCT01567800 2026-03-06

Prostate Hypoxia FAZA

University Health Network, Toronto

Phase NA Completed
18 enrolled
Genitourinary

Prostatic Neoplasms

NCT03955393 2020-12-22

FAZA

IRCCS San Raffaele

Completed
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡